Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RAVULIZUMAB vs ZILUCOPLAN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RAVULIZUMAB vs ZILUCOPLAN: Safety Overview

Metric RAVULIZUMAB ZILUCOPLAN
Total FAERS Reports 118 441
Deaths Reported 11 23
Death Rate 9.3% 5.2%
Hospitalizations 89 163
Average Patient Age 48.4 yrs 58.8 yrs
% Female Patients 56.3% 53.6%
FDA Approval Date N/A Oct 17, 2023
Manufacturer Alexion Pharmaceuticals Inc. UCB, Inc.
Route INTRAVENOUS SUBCUTANEOUS
Marketing Status N/A Prescription